![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Nyxoah’s Next-Generation Genio 2.1 System Gets CE Mark
Nyxoah’s Next-Generation Genio 2.1 System Gets CE Mark
Nyxoah has received a CE mark for additional components for its Genio 2.1 system for treatment of patients with obstructive sleep apnea, a respiratory disorder marked by blockage of the upper airway during sleep.
The next-generation system, which includes a new smartphone application and an upgraded external activation chip, provides daily feedback on therapy usage and enables adjustments to the level of stimulation.
Physicians can fine-tune the stimulation to determine the optimal level of comfort for patients without compromising therapy efficacy. The additional features do not require a surgical procedure to replace the implantable component that is already in place, the Belgium-based company said.
Upcoming Events
-
21Oct